United Therapeutics stock kpis
Want to see UTHR full AI Analyst Report?
Revenue by Segment
United Therapeutics reported revenue by segment of $832.50M in Q3 2026, up 6.3% from Q2 2026 and up 4.1% year over year. This is the highest value since 2019.
Separates income from core drug sales, services, licensing, and any organ- or device-related activities to show which parts of the business drive profit and growth. High concentration in a small number of therapies raises patent and competition risk, while a rising share from newer products, services, or recurring programs signals diversification and potential margin improvement.
Tyvaso remains the clear revenue engine—its multi‑year climb has slowed and recently flattened amid competitive pressure even as starts/referrals and patient counts hit records; management doubled the sales force and pushed major filings (Tyvaso IPF sNDA, ralinepag NDA), so 2027 approvals could drive a material upside and justify the narrowed path to a ~$4B run‑rate. Legacy drugs (Remodulin, Orenitram, Unituxin) supply a stable base, but near‑term revenue is uncertain given sales lag versus patient metrics and peer uptake risk.
UTHR Revenue by Segment
| Period | Other | Tyvaso | Remodulin | Orenitram | Unituxin | Adcirca | Total |
|---|---|---|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $4.90M | $503.80M | $122.00M | $145.00M | $52.30M | $4.50M | $832.50M |
| Q2 2026Jun 30, 2026 | $6.80M | $452.60M | $126.30M | $125.70M | $65.20M | $6.70M | $783.30M |
| Q1 2026Mar 31, 2026 | $5.30M | $457.50M | $126.60M | $135.60M | $53.60M | $2.90M | $781.50M |
| Q4 2025Dec 31, 2025 | $6.60M | $464.30M | $128.00M | $121.20M | $62.30M | $7.80M | $790.20M |
| Q3 2025Sep 30, 2025 | $6.90M | $478.00M | $125.90M | $131.10M | $47.90M | $9.70M | $799.50M |
| Q2 2025Jun 30, 2025 | $5.50M | $469.60M | $134.70M | $123.90M | $58.40M | $6.50M | $798.60M |
| Q1 2025Mar 31, 2025 | $5.00M | $466.30M | $138.20M | $120.70M | $58.20M | $6.00M | $794.40M |
| Q4 2024Dec 31, 2024 | $5.50M | $415.90M | $134.50M | $107.80M | $67.50M | $4.70M | $735.90M |
| Q3 2024Sep 30, 2024 | $5.50M | $433.80M | $128.30M | $113.20M | $61.10M | $7.00M | $748.90M |
| Q2 2024Jun 30, 2024 | $4.90M | $398.20M | $147.30M | $107.10M | $51.70M | $5.70M | $714.90M |
| Q1 2024Mar 31, 2024 | $6.20M | $372.50M | $128.00M | $106.20M | $58.40M | $6.40M | $677.70M |
| Q4 2023Dec 31, 2023 | $3.90M | $350.60M | $115.10M | $84.10M | $54.20M | $6.80M | $614.70M |
| Q3 2023Sep 30, 2023 | $1.90M | $325.80M | $131.10M | $92.00M | $51.30M | $7.30M | $609.40M |
| Q2 2023Jun 30, 2023 | $0.00 | $318.90M | $127.20M | $95.10M | $44.30M | $7.50M | $593.00M |
| Q1 2023Mar 31, 2023 | $2.50M | $238.40M | $121.40M | $88.20M | $49.10M | $7.30M | $506.90M |
| Q4 2022Dec 31, 2022 | $3.80M | $242.30M | $122.50M | $75.80M | $36.70M | $10.40M | $491.50M |
| Q3 2022Sep 30, 2022 | $0.00 | $257.70M | $114.00M | $87.50M | $46.10M | $10.70M | $516.00M |
| Q2 2022Jun 30, 2022 | $0.00 | $201.00M | $132.00M | $79.00M | $44.50M | $10.40M | $466.90M |
| Q1 2022Mar 31, 2022 | $10.00M | $172.00M | $131.70M | $82.80M | $55.60M | $9.80M | $461.90M |
| Q4 2021Dec 31, 2021 | $0.00 | $166.50M | $118.30M | $72.30M | $50.00M | $8.10M | $415.20M |
| Q3 2021Sep 30, 2021 | $0.00 | $164.20M | $125.40M | $85.20M | $55.30M | $14.60M | $444.70M |
| Q2 2021Jun 30, 2021 | $0.00 | $153.80M | $139.80M | $76.20M | $53.10M | $23.60M | $446.50M |
| Q1 2021Mar 31, 2021 | $0.00 | $123.00M | $130.20M | $72.40M | $43.90M | $9.60M | $379.10M |
| Q4 2020Dec 31, 2020 | $0.00 | $131.70M | $127.90M | $74.00M | $29.70M | $21.60M | $384.90M |
| Q3 2020Sep 30, 2020 | $0.00 | $129.50M | $124.50M | $74.70M | $37.60M | $13.80M | $380.10M |
| Q2 2020Jun 30, 2020 | $0.00 | $119.20M | $119.00M | $75.40M | $29.00M | $19.40M | $362.00M |
| Q1 2020Mar 31, 2020 | $0.00 | $102.90M | $145.30M | $69.00M | $26.60M | $12.50M | $356.30M |
| Q4 2019Dec 31, 2019 | $0.00 | $91.40M | $107.40M | $50.90M | $33.60M | $27.80M | $311.10M |

